openPR Logo
Press release

Transdermal Drug Delivery Market Sales Revenue Clinical Trials Pipeline Report

07-04-2017 07:13 AM CET | Health & Medicine

Press release from: Kuick Resarch

Transdermal Drug Delivery Market Sales Revenue Clinical Trials

Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation.

Download Report:

https://www.kuickresearch.com/report-Transdermal-Drug-Delivery-Market-&-Clinical-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

1. Introduction to Transdermal Drug Delivery

2. Transdermal Drug Delivery Mechanism
2.1 Mechanisms of Transdermal Drug Delivery
2.2 Types of Transdermal Patch

3. Why Need For Transdermal Drug Delivery?

4. Transdermal Drug Delivery Market Outlook
4.1 Market Overview
4.2 Clinical Pipeline Analysis

5. Transdermal Drug Delivery Market Dynamics
5.1 Favorable Market Drivers
5.2 Key Issues to be Discussed

6. Future of Transdermal Drug Delivery Market

7. Guidelines/Regulations for Transdermal Drug Delivery
7.1 EMA Guideline for Quality of Transdermal Patches
7.2 FDA Guidelines for Residual Drug in Transdermal & Related Drug Delivery Systems

8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications
8.1 Unknown Phase
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase I
8.6 Phase I/II
8.7 Phase II
8.8 Phase III
8.9 Preregistration
8.10 Registered

9. Marketed Transdermal Drug Profiles

10. Suspended & Discontinued Transdermal Drug Profiles
10.1 No Development Reported
10.2 Discontinued
10.3 Market Withdrawal
10.4 Suspended

11. Competitive Landscape
11.1 Acrux
11.2 ANI Pharmaceuticals
11.3 Antares Pharma
11.4 Bayer HealthCare Pharmaceuticals
11.5 Dermatrends Inc.
11.6 Durect Corporation
11.7 Nuvo Research
11.8 Novartis
11.9 Phosphagenics
11.10 Zosano Pharma

Figure 1-1: Drug Delivery Methods
Figure 2-1: Transdermal Drug Delivery Mechanism
Figure 4-1: Composition of Drug Delivery Market
Figure 4-2: Global Transdermal Drug Delivery Market (US$ Billion), 2013-2018
Figure 4-3: Regional Market for Transdermal Drug Delivery
Figure 4-4: Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-5: Number of Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 4-6: Inactive Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-7: Number of Inactive Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 4-8: No Development in Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-9: Number of No Development in Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 4-10: Discontinued Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-11: Number of Discontinued Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 4-12: Suspended Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-13: Number of Suspended Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 6-1: Developments in Transdermal Drug Delivery
Figure 11-1: Acrux Clinical Pipeline
Figure 11-2: Antares Pharma Clinical Pipeline
Figure 11-3: DURECT Corporation Clinical Pipeline
Figure 11-4: Phosphagenics Clinical Pipeline
Figure 11-5: Zosano Pharma Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Transdermal Drug Delivery Market Sales Revenue Clinical Trials Pipeline Report here

News-ID: 606845 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Transdermal

Global Transdermal Skin Patches Market | Global Transdermal Skin Patches Industr …
The transdermal skin patches market comprises of sales of transdermal skin patches products and connected services utilize to deliver medicine to the human body through patches. The Transdermal skin patches comprise the usage of adhesive patches made up of polymers that comprises drugs. The drug from such patches are absorbed into the body and ultimately into the blood stream disregarding the drug delivery through pill, or injections. According to the
Transdermal Patch Market Report 2018: Segmentation by Product (Fentanyl Transder …
Global Transdermal Patch market research report provides company profile for Actavis, Mundipharma, Henan Lingrui Pharmaceutical, Changzhou Siyao, Rfl Pharmaceutical, Hisamitsu Pharmaceutical, Novartis, Johnson & Johnson, Teikoku Pharma, Mylan and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018
Transdermal Scopolamine Market Evolution / Developments
A new study by Transparency Market Research (TMR) indicates that Novartis AG, alone, contributed nearly 41.0% of the overall revenue of the global transdermal scopolamine market in 2016. Other two torch bearers in the market, namely, GlaxoSmithKline Plc and Baxter International Inc., commanded a cumulative share of 49.0% in the same year. Even though, the number of small players in the market is less, the degree of competition within the
Transdermal Drug Delivery System Market 2017 -
Apex Research, recently published a detailed market research study focused on the "Transdermal Drug Delivery System Market" across the global, regional and country level. The report provides 360° analysis of "Transdermal Drug Delivery System Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Transdermal Drug Delivery System industry, and estimates the future
US Transdermal Patch Market US Transdermal Sales Report 2020
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Transdermal Patch 2. Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch 3. Why There Exist Need for Transdermal Patches? 4. Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of
Transdermal Patch Market Transdermal Patch Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Transdermal Patch Classification of Transdermal Patches 2.1 Single/ Multiple-Layer Drug-in-Adhesive 2.2 Reservoir Transdermal Patches 2.3 Matrix Based Transdermal Patches 2.4 Vapor Patch 2.5 Active and Passive Patch Why There Exist Need for Transdermal Patches? Mechanism of Transdermal Patch Drug Delivery 4.1 Properties of Transdermal Therapeutics 4.2 Components of Transdermal Patch 4.3